This story highlighted a difference between the way mitral valve problems are commonly treated and the treatment recommended in the guidelines (American College of Cardiology/American Heart Association – though this guideline source was not actually mentioned in the article). It provided some insight for individuals who might be making a decision about treatment for this specific problem, but also for helping people in general think about questions they might want to get answers to for whatever ailment they are seeking relief for. Discussed within the story was the trade-off between convenience of treatment and the wisdom of seeking treatment in a high-volume center for people to weigh whenever they are contemplating invasive therapy.
There was no estimate for the cost for either mitral valve repair or replacement, though the story did raise the insurance coverage issue.
The story should have compared and quantified the benefits of mitral valve repair with mitral valve replacement.
The story mentioned that with mitral valve replacement there were medications that would need to be taken for the rest of the patient’s life, and that there was an expectation that the valve would need replacement again in 10 to 12 years.
While mentioning guideline recommendations for mitral valve surgical interventions, it would have been useful for readers to provide some detail about those guidelines. When discussing the guidelines "issued here in 2006", it would appear that the story was referring to those issued by the American College of Cardiology/American Heart Association. It is helpful for readers to know the source of the recommendations so they can have a context for the value of that recommendation.
Though the story did not engage in disease mongering, it presented the sobering notion that thousands of individuals who undergo surgery for a leaky mitral valve are not receving the treatment.
One expert, who does not appear to be directly associated with the guidelines referred to in the article itself, was quoted in this piece.
The story was about two surgical treatments for dealing with mitral valve problems – repair and replacement. It offered information about the underutilization of mitral valve repair. It did not contain information about the natural history of mitral valve ‘problems’, and included nothing about the option of having neither treatment.
The story mentioned that only half of patients having surgery for leaky mitral valves have them repaired, which was deemed ‘unacceptable’ by the expert quoted. The story explained that this treatment was not readily available and that for many, it would require ‘distant referral’.
The story highlighted underutilization of mitral valve repair as opposed to mitral valve replacement..
Des not appear to rely on a press release
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.